Login
Navigate Fool.com
Will RDY beat
the market?
Community Rating: 4 Stars: Favorite

42.54 -0.30 (-0.70%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $42.11
Previous Close $42.84
Daily Range $41.95 - $42.51
52-Week Range $31.32 - $47.93
Market Cap $7.2B
P/E Ratio 23.67
Dividend (Yield) $0.26 (0.5%)
Ex-Dividend Date
Dividend Pay Date
07/10/13
08/15/13
Volume 88,337
Average Daily Volume 310,679
Current FY EPS $2.18

How do you think RDY
will perform against the market?

Top RDY Bull/Bear Pitches

 

NHWeston (9.85)
Submitted April 2, 2010

Dr. Reddy's is a rapidly growing player in the global generics market. For now, they virtually own their domestic market in India and, although overshadowed by more flashy companies like Teva, they ar … More

0 Replies Reply Report this Post
 

SCSDogz (0)
Submitted September 16, 2008

I see bright things for this company in the future. They have a 4 biologics in the pipeline and 3 acquisitions over the last couple years. But these will not bear fruit for a while. Also RDY is still … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

Wednesday’s Top Health Care Stories: Zogenix, Endo, and Teva

Zogenix, Endo, and Teva could make waves across the health sector this Wednesday morning.

Galena Biopharma Earnings Report: "P.S. -- We're Under Investigation"

Galena reports fourth-quarter earnings and one other "trivial" detail -- an SEC investigation.

Today’s Top Health Care Stories: Dr. Reddy’s Labs, Jazz, and Sanofi

Dr. Reddy’s Labs, Jazz, and Sanofi could all make health care headlines this morning. Here’s why.

Which Indian ADRs Are Shining Despite the Country's Slowdown?

Check out Infosys, Dr. Reddy's Laboratories, and Wipro. You'll be surprised.

Galena Biopharma, Dr. Reddy's Sign NeuVax Licensing Pact for India

Dr. Reddy's Laboratories will hold the commercial rights for Galena's NeuVax, and head the development of the drug to treat gastric cancer.

Eli Lilly Sees Generic Competition for Cymbalta (x6)

Dr. Reddy's Laboratories, Teva Pharmaceuticals, and others gain FDA approval for generic versions of Eli Lilly's Cymbalta.

Can This Big Biotech Keep Outperforming Its Industry Peers?

Shares of Celgene have risen more than 100% over the past 12 months. Can it keep climbing, or is it time for investors to take profits?

Dr. Reddy’s Announces the Approval of Azacitidine for Injection

Positive Outlook for the Generic Version of Depakote ER

Since 1983, Depakote ER has been a good source of revenue for drug manufacturers. But is its future as sunny?

Dr. Reddy’s Announces the Launch of Divalproex Sodium Extended - Release Tablets, USP

See More RDY News...

Sector

Healthcare

Industry

Drugs

Dr. Reddy's Laboratories (RDY) Description

A global pharmaceutical company, which produces pharmaceutical ingredients and intermediates, finished dosage forms and biotechnology products and markets them globally. It conducts research in the areas of cancer, diabetes, cardiovascular disease etc. Website: http://www.drreddys.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks